JPMorgan analyst Richard Vosser downgraded Roche to Underweight from Neutral with a price target of CHF 275, down from CHF 300. The analyst continues to see a "bifurcation" in European pharma company outlooks in 2023, both in terms of pipeline readouts and longer-term where "genericisations again need to be navigated." As such, he would avoid companies like GSK and Roche, seeing downside to 2023 consensus estimates and "potentially challenged" 2025-2030 outlooks. Vosser continues to favor companies "which have sustainably higher growth" and "far more" pipeline data points, new launches to drive estimate upgrades.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on RHHBY:
- FDA approves Roche’s Lunsumio, a first-in-class bispecific antibody, to treat people with relapsed or refractory follicular lymphoma
- Genentech announces FDA approval of Lunsumio
- FDA approves Genentech’s Lunsumio in refractory follicular lymphoma
- FDA approves Roche’s Actemra for the treatment of COVID-19 in hospitalised adults
- FDA approves Genentech’s Actemra for treatment of COVID-19 hospitalized adults